Renaissance Capital’s AbCellera Biologics ABCL Stock Holding History

Renaissance Capital’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,957	Closed	-$60K	–	76
2023 Q1	$60K	Sell	7,957 -1,019	-11%	-$9.25K	0.04%	87
2022 Q4	$90.9K	Buy	+8,976	New	+$104K	0.07%	86
2022 Q1	–	Sell	-10,327	Closed	-$148K	–	101
2021 Q4	$148K	Sell	10,327 -1,815	-15%	-$27.5K	0.04%	107
2021 Q3	$243K	Sell	12,142 -16,349	-57%	-$289K	0.05%	100
2021 Q2	$627K	Sell	28,491 -6,270	-18%	-$173K	0.1%	71
2021 Q1	$1.18M	Buy	+34,761	New	+$1.38M	0.17%	57

Other funds holding ABCL

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

FFVM

Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Renaissance Capital's ABCL Position: Q2 2023 in Review

Renaissance Capital sold out of AbCellera Biologics (ABCL) in Q2 2023, closing a stake of 7,957 shares — an estimated $60K sold.

Renaissance Capital first reported a position in ABCL in Q1 2021 and held it in 6 quarters. The position peaked at $1.18M in Q1 2021. 169 funds tracked by Wall St. Rank hold ABCL as of Q2 2023.

Renaissance Capital reported no remaining AbCellera Biologics position as of Q2 2023 after selling out during the quarter.
Renaissance Capital sold 7,957 AbCellera Biologics shares in Q2 2023, an estimated $60K.
Renaissance Capital first reported a position in AbCellera Biologics in Q1 2021 and held it in 6 quarters.
Renaissance Capital's AbCellera Biologics position peaked at $1.18M in Q1 2021.
169 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2023.

Based on Renaissance Capital's 13F filing for Q2 2023, filed 17 Jul 2023.